|Bid||0.00 x 1400|
|Ask||95.50 x 900|
|Day's Range||90.76 - 97.43|
|52 Week Range||3.65 - 189.40|
|Beta (5Y Monthly)||1.64|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||186.20|
With three vaccine candidates out with a first look at efficacy data, Wall Street is more optimistic about the light at the end of the pandemic tunnel.
Now that Moderna and Pfizer have both announced that their coronavirus vaccine candidates appear to be effective at preventing infection, distant laggards look less desirable than ever. Inovio Pharmaceuticals (NASDAQ: INO), Vaxart (NASDAQ: VXRT), and Novavax (NASDAQ: NVAX) aren't going to start selling their candidates to the public anytime soon, but they could still be lucrative stocks. All three have moved more slowly than Moderna and Pfizer, but they share one of the same challenges.
U.S. cases surpass 12 million as positive vaccine and antibody treatment news provide hope.